Of the arboviruses that are NIAID Category A, B and C Priority Pathogens, approved vaccines are available only for Japanese encephalitis virus, tick-borne encephalitis virus, and yellow fever virus (YFV). Additionally, use of even the highly effective YFV17D vaccine is now being re-evaluated due to increasing reports of severe adverse events following vaccination, particularly in immunocompromised patients. There are currently no other prophylactic or therapeutic strategies approved for arbovirus diseases. Thus, we propose to investigate the utility of human (Hu) and humanized murine (MuHu) arbovirus-specific monoclonal antibodies (MAbs) as antiviral prophylactic or therapeutic reagents. Initial studies, including those in our Progress Report below, indicate that MAbs can be effective prophylactic and therapeutic agents for the encephalitic West Nile and Venezuelan equine encephalitis viruses (VEEV) in mouse models of infection. Based on these results we hypothesize that antiviral MAb prophylaxis and/or therapy using Hu- or MuHuMAbs will also be successful for the viscerotropic, Category A and C arboviruses dengue (DENV) and yellow fever (YFV). We will continue to assess the protective and therapeutic capacities of HuMAb for VEEV developed during our first grant period and will use two approaches to develop YFV and DENV2-reactive HuMAb or MuHuMAb. 1) Use new cell fusion partners, MFP2 or MFP2D cells, to prepare human hybridomas using either human peripheral blood B-cells from infection-immune persons, or human B-cells from virus-immunized, humanized mice. 2) Genetically recombine the variable regions of protective murine MAbs with the constant regions of human immunoglobulin. Protective and therapeutic capacity of these MAbs will be tested by peripheral virus challenge of outbred mice (VEEV) or inbred mice deficient in their interferon response (YFV and DENV2).
Specific aims are as follows: 1. Continue characterization and assessment of protective and therapeutic capacities of human or humanized VEEV-reactive MAbs and map the human anti-VEEV repertoire. 2. Develop HuMAbs and MuHuMAbs specific for YFV and DENV2 Eproteins. 3. Develop a new peripheral challenge animal model for YF using YFV17D vaccine in interferondeficient AG129 mice. 4. Characterize the ability of the YFV- and DENV2-reactive MuHuMAbs and HuMAbs to protect from or treat YFV and DENV2 infections in the AG129 mouse model and use the HuMAbs to map the human anti-E protein antibody repertoire. This project fits within the RMRCE Integrated Research Focus on Viral Therapeutics and will interact directly with RPs 3.1 and 1.7 and Core C.

Public Health Relevance

There are few vaccines and no antiviral therapeutics available for use in human infections with the emerging, medically important arboviruses Venezuelan equine encephalitis (VEEV), yellow fever (YFV) or dengue (DENV) viruses. This project will develop safe and effective human antibodies that can be used in preventing or curing human VEEV, YFV or DENV infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-09
Application #
8465806
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
9
Fiscal Year
2013
Total Cost
$201,564
Indirect Cost
$51,621
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Knudson, Susan E; Cummings, Jason E; Bommineni, Gopal R et al. (2016) Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:8-14
Charley, Phillida A; Wilusz, Jeffrey (2016) Standing your ground to exoribonucleases: Function of Flavivirus long non-coding RNAs. Virus Res 212:70-7
Phillips, Aaron T; Rico, Amber B; Stauft, Charles B et al. (2016) Entry Sites of Venezuelan and Western Equine Encephalitis Viruses in the Mouse Central Nervous System following Peripheral Infection. J Virol 90:5785-96
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8
Shankar, Sundaresh; Whitby, Landon R; Casquilho-Gray, Hedi E et al. (2016) Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol 90:6799-807
York, Joanne; Nunberg, Jack H (2016) Myristoylation of the Arenavirus Envelope Glycoprotein Stable Signal Peptide Is Critical for Membrane Fusion but Dispensable for Virion Morphogenesis. J Virol 90:8341-50
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Voge, Natalia V; Perera, Rushika; Mahapatra, Sebabrata et al. (2016) Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. PLoS Negl Trop Dis 10:e0004449
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39

Showing the most recent 10 out of 244 publications